Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06064851 · ClinicalTrials.gov registry record · NA

Delivering Transcutaneous Auricular Neurostimulation to Reduce Heavy Menstrual Bleeding in Patients With and Without Von Willebrand Disease

A NA study of Heavy Menstrual Bleeding and Von Willebrand Disease, Type 1, sponsored by Five Liters.

Completed
Registry status
NA
Development phase
29
Enrollment target
1
Study location

NCT06064851 is a NA study of Heavy Menstrual Bleeding and Von Willebrand Disease, Type 1 that has completed, run by Five Liters. The registered enrollment target is 29 participants, below the 222-participant average among 9 other Heavy Menstrual Bleeding trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06064851, a NA study of Heavy Menstrual Bleeding and Von Willebrand Disease, Type 1, has completed, sponsored by Five Liters.

COMPLETED
Registry status
NA
Development phase
29 participants
Enrollment target
1
Study location

Study Summary

The objectives of this study are to determine if transcutaneous auricular neurostimulation (tAN) can modulate hemostasis, improve perceived quality of life, and improve pain during the menstrual cycle of von Willebrand Disease (VWD) patients.

Interventions

  • DEVICE Volta System

Study Locations (1)

Texas

  • Five Liters - Dallas

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2023-10-27
Est. Completion 2025-04-18
Phase NA

Sponsor

Five Liters

1 total trials

What the Registry Record Tells You About NCT06064851

The ClinicalTrials.gov registry entry for NCT06064851 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 222-participant average among 9 other Heavy Menstrual Bleeding trials with a reported enrollment target (87% lower). The listed sponsor is Five Liters, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Heavy Menstrual Bleeding appearing as the primary indexed condition, and to 1 intervention - of which Volta System is the first listed.

NCT06064851 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT06064851 about?

NCT06064851 is a clinical study titled "Delivering Transcutaneous Auricular Neurostimulation to Reduce Heavy Menstrual Bleeding in Patients With and Without Von Willebrand Disease". The objectives of this study are to determine if transcutaneous auricular neurostimulation (tAN) can modulate hemostasis, improve perceived quality of life, and improve pain during the menstrual cycle of von Willebrand Disease (VWD) patients.

What is the current status of trial NCT06064851?

This trial is currently completed. It is a NA study. The enrollment target is 29 participants. The study started on 2023-10-27. Estimated completion is 2025-04-18.

What conditions does trial NCT06064851 study?

This clinical trial studies the following conditions: Heavy Menstrual Bleeding, Von Willebrand Disease, Type 1.

What interventions are being tested in trial NCT06064851?

The interventions under investigation include: Volta System (DEVICE).

Who is sponsoring clinical trial NCT06064851?

This trial is sponsored by Five Liters, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06064851 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heavy Menstrual Bleeding

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.